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A large subgroup of around 25% of schizophrenia patients suffers from
obsessive-compulsive symptoms (OCS) and about 12% fulfill the diagnostic criteria
of an obsessive-compulsive disorder (OCD). The additional occurrence of OCS is
associated with high subjective burden of disease, additional neurocognitive impairment,
poorer social and vocational functioning, greater service utilization and high levels of
anxiety and depression. Comorbid patients can be assigned to heterogeneous subgroups.
One hypothesis assumes that second generation antipsychotics (SGAs), most importantly
clozapine, might aggravate or even induce second-onset OCS. Several arguments support
this assumption, most importantly the observed chronological order of first psychotic
manifestation, start of treatment with clozapine and onset of OCS. In addition, correlations
between OCS-severity and dose and serum levels and duration of clozapine treatment hint
toward a dose-dependent side effect. It has been hypothesized that genetic risk-factors
dispose patients with schizophrenia to develop OCS. One study in a South Korean sample
reported associations with polymorphisms in the gene SLC1A1 (solute carrier family 1A1)
and SGA-induced OCS. However, this finding could not be replicated in European patients.
Preliminary results also suggest an involvement of polymorphisms in the BDNF gene
(brain-derived neurotrophic factor) and an interaction between markers of SLC1A1 and the
gene DLGAP3 (disc large associated protein 3) as well as GRIN2B (N-methyl-D-aspartate
receptor subunit 2B). Further research of well-defined samples, in particular studies
investigating possible interactions of genetic risk-constellations and pharmacodynamic
properties, are needed to clarify the assumed development of SGA-induced OCS. Results
might improve pathogenic concepts and facilitate the definition of at risk populations,
early detection and monitoring of OCS as well as multimodal therapeutic interventions.
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GENE AND ENVIRONMENT INTERACTIONS IN PSYCHIATRIC
DISORDERS
Several frequent and disabling mental disorders manifest as
a consequence of both genetic and environmental factors.
Schizophrenia for instance is commonly perceived on the back-
ground of a gene-and-environment interaction (GxEI), where
individual genetic properties dispose to a specific liability and
sensitivity for specific stressors. These could include migration,
other stressful life events, or effects of psychotropic substances
(van Os and Kapur, 2009; van Os et al., 2008, 2010). Similar
concepts were suggested regarding depression (Keers and Uher,
2012), anxiety disorders (Gregory et al., 2008; Nugent et al.,
2011) and obsessive-compulsive disorder (OCD) (Nicolini et al.,
Abbreviations: AMS, amisulpride; APZ, aripiprazole; ARMS, at risk mental state;
BDNF, brain derived neurotrophic factor; CBT, cognitive behavioral therapy; CLZ,
clozapine; DLGAP3, disks large associated protein 3; GxEI: Gene and environment
interaction; OCS, obsessive-compulsive symptoms; OCD, obsessive-compulsive
disorder; OLZ, olanzapine; SGA, second generation antipsychotics; SLC1A1, solute
carrier family gene 1A1; SNP, single nucleotide polymorphism; SSRI, selective
serotonin reuptake inhibitor.
2009; Pauls, 2010). Expanding the view to common comor-
bidities it is even more complex and demanding to inves-
tigate whether these might also be described on the basis
of GxEI.
In this review we summarize evidence investigating possi-
ble pharmacological and genetic risk constellations underlying
the co-occurrence of comorbid obsessive-compulsive symptoms
(OCS) in schizophrenia.
EPIDEMIOLOGY OF OCS IN SCHIZOPHRENIA
Patients with schizophrenia have a high lifetime risk of about
25% for comorbid OCS and a recent meta-analysis reports that
12.1% also fulfill the criteria for an OCD (Figure 1C; Poyurovsky
et al., 2004, 2012; Buckley et al., 2009; Lysaker and Whitney,
2009; Mukhopadhaya et al., 2009; Achim et al., 2011; Hadi et al.,
2011). In contrast, prevalence rates of 1–2% for OCD in the gen-
eral population are considerably lower (Murphy et al., 2010).
Accordingly, primary OCD-patients carry a relatively low risk
(1.7%) to develop comorbid psychotic symptoms (de Haan et al.,
2009).
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FIGURE 1 | Prevalence estimations of OCS and OCD within different
samples of patients. (A) Mean prevalence rates in ARMS studies. (B)
Mean prevalence rates in first-episode psychotic patients. (C) Mean
prevalence rates in patients suffering from chronic schizophrenia.
Schizophrenia patients, who suffer from comorbid OCS often
also display pronounced and sometimes treatment resistant posi-
tive and negative symptoms (Cunill et al., 2009; Sa et al., 2009).
In addition, they present with specific neurocognitive deficits
(Schirmbeck et al., 2012b), more often utilize health care services
(Berman et al., 1995a), and show heightened levels of anxiety
and depression (Lysaker and Whitney, 2009) when compared to
schizophrenia patients without OCS. These pronounced impair-
ments result in an additional burden of disease, in poorer social
and vocational function (Fenton and McGlashan, 1986; Lysaker
et al., 2004; Öngür and Goff, 2005; de Haan et al., 2013) and in a
less favorable overall prognosis (Schirmbeck and Zink, 2013).
CLINICAL PRESENTATION AND EXPLANATORY CONCEPTS
Several heterogeneous subgroups of comorbid patients have been
suggested depending on the diverse clinical course and phe-
notypic presentation. In order to unravel the specific interplay
of genetic, psychosocial and pharmacological factors current
research tries to focus on homogeneous subgroups. Subdivisions
into such subgroups can for example be achieved according to the
time point of first manifestation of comorbidOCS and the clinical
course.
ONSET OF OCS
First onset of OCS has been described at different stages during
the course of psychotic illness:
(1) Before psychosis as independent, co-existing symptoms or
diagnosed OCD.
(2) Prior to psychotic manifestation as part of the at risk mental
state (ARMS).
(3) Simultaneously with the first manifestation of psychosis.
(4) After the first psychotic episode during the course of chronic
schizophrenia.
(5) As de novo OCS after initiation of antipsychotic treatment.
A remarkably large subgroup of patients already suffers fromOCS
during ARMS. Overall, sample-size weighted mean prevalence
rates show that 12.1% (CI: 9.4–14.8%) of ARMS patients report
OCS (Shioiri et al., 2007; Niendam et al., 2009; Bechdolf et al.,
2011; Sterk et al., 2011; Hur et al., 2012), while 5.2% (CI: 4.1–
6.3%) fulfill the criteria for OCD (Shioiri et al., 2007; Niendam
et al., 2009; Rubino et al., 2009; Bechdolf et al., 2011; Fontenelle
et al., 2011; DeVylder et al., 2012; Fusar-Poli et al., 2012; Sterk
et al., 2011) (Figure 1A). Slightly higher averaged rates for OCS
(17.1%, CI: 14.0–20.2) and OCD (7.3%, CI: 5.3–9.3%) can be
found in first episode patients (Figure 1B; Poyurovsky et al.,
1999a; de Haan et al., 2004; Sterk et al., 2011; de Haan et al.,
2012; Zink et al., under review). Large variability of epidemio-
logical data between studies can be explained by differences in
the definition of ARMS criteria and differences in the psychome-
tric assessment of OCS or OCD. Regarding the impact of OCS
during the ARMS on other clinical variables, findings have been
heterogeneous. Whereas higher impairment of psychosocial func-
tioning (de Haan et al., 2012; DeVylder et al., 2012; Fusar-Poli
et al., 2012; Hur et al., 2012) and more severe depressive symp-
toms (Niendam et al., 2009; DeVylder et al., 2012; Fontenelle
et al., 2012; de Haan et al., 2013) have consistently been reported,
findings regarding transition rates into psychosis (Niendam et al.,
2009; Fontenelle et al., 2011, 2012; Fusar-Poli et al., 2012) and
cognition (Van Dael et al., 2011){4854}(Hur et al., 2012) are
contradicting.
Apart from OCS during the ARMS a growing body of evi-
dence investigated the co-occurrence of OCS during mani-
fest schizophrenia. A significant subgroup within these patients
reports OCS development after treatment-start with second gen-
eration antipsychotic agents (SGA). The order of the three
events “onset of psychosis,” “start with SGA treatment” and
subsequent “de novo development of OCS” hints toward the
involvement of pharmacodynamic mechanisms (see Figure 2E
and detailed description in section OCS induced by second-
generation antipsychotics).
CLINICAL COURSE
In addition to varying time-points of first manifestation of
OCS, the course of symptom severity over time also differs
(Figure 2). OCS may appear as fluctuating symptoms, they
may resolve, persist or even worsen over time. Within those
patients who already reported manifest OCD prior to the psy-
chotic illness, e.g., as adolescents, OCS will most likely persist
or worsen independent of the course of schizophrenia (Hwang
et al., 2009). Within those individuals who develop OCS some-
time during the course of schizophrenia, only scarce longitu-
dinal studies examined quantitative changes over time. One
large investigation from the Netherlands followed participants
over a period of 5 years and described a predominantly fluc-
tuating course of OCS severity in over 70% of the comorbid
sample: Some patients experienced the remission of OCS, oth-
ers a fluctuating, more or less cyclic course, some reported
first onset of OCS, whereas a forth group showed persisting
symptom severity (Mahasuar et al., 2011). Another longitudi-
nal study in a German sample investigated two pharmacolog-
ical diverse groups and found persisting OCS severity over 12
months in the group treated with clozapine (CLZ) and olan-
zapine (OLZ) (Schirmbeck et al., 2012b, 2013). The diverse
clinical course adds to the heterogeneous clinical presentation
and suggests an involvement of different environmental fac-
tors and/or symptom interactions in the longitudinal devel-
opment of comorbid OCS in schizophrenia (see section
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FIGURE 2 | OCS might manifest at different time points during the
course of schizophrenia illness. In addition, the clinical course is highly
variable. Blue symbols indicate the onset and severity of OCS, red ones are
related to psychotic symptoms. (A) Pre-existing and persistent OCS. (B)
Intermittent OCS during ARMS or later in the clinical course. (C) OCS-onset
during ARMS and persistent course, strongly associated to the psychotic
symptoms (schizo-obsessive concept). (D) Fluctuating course of OCS. (E)
Second-onset OCS during antipsychotic treatment.
Underlying neurobiological mechanisms and environmental
factors).
Furthermore, specific symptom dimensions of schizophrenia
might overlap with the obsessive-compulsive phenotype (Fink
and Taylor, 2001), making a careful differentiation and classi-
fication of presented symptoms necessary. Especially in cases
of catatonic schizophrenia (Fink, 2013), a reliable assessment
with established psychometric scales such as the catatonia rating
scale (CRS) (Bräunig et al., 2000) and the Yale-Brown-Obsessive-
Compulsive Scale (YBOCS) (Woody et al., 1995; de Haan et al.,
2006) is often difficult. Historically, a more precise character-
ization was achieved by an undisguised view on the natural
long-term course of schizophrenia, for instance published by
Karl Leonhard (Beckmann et al., 2000). These descriptions allow
clear discrimination between OCS and catatonic symptoms most
importantly in patients with so-called “manneristic catatonia.”
Clinical research and an improved pathogenic understanding
of OCS in patients with schizophrenia is thus dependent on a
careful exploration of symptoms. Several aspects help to discrimi-
nate delusions or hallucinations from typical OCS to ensure valid
and reliable diagnosis (see Table 1).
PATHOGENIC CONCEPTS
In attempts to explain the co-occurrence of OCS in schizophre-
nia, heterogeneous, partly overlapping but also contradicting
pathogenic concepts have been suggested.
The two rather common psychiatric syndromes could of
course develop independently, representing a random associa-
tion. Based on the above mentioned high prevalence rates and
diverse clinical presentation this cannot be the only explanation
for OCS in nearly every fourth patient with schizophrenia.
Early concepts assumed that patients with schizophre-
nia develop OCS as an attempt to reduce psychotic symp-
toms and thus, the presence of OCS was proposed to have
protective effects regarding psychotic disintegration, based
on single-case analyses or small case series (Stengel, 1945;
Dowling et al., 1995). Similarly, Guillem et al. described
negative correlations between specific OCS and the sever-
ity of psychotic disorganization in thinking and behavior,
proposing compensating mechanisms (Guillem et al., 2009).
However, in a broader perspective, subsequent research revealed
higher severity of psychotic symptoms and more functional
impairment if OCS were present (Cunill et al., 2009) (see
above).
Approaching the co-occurrence from the OCD spec-
trum, the concept of “schizotypic OCD” has been described
(Poyurovsky and Koran, 2005; Poyurovsky et al., 2008). This
concept assumes that primary OCD-patients present beliefs,
which can be classified on a spectrum between obsessions
and delusions emphasizing the similarities as being irra-
tional thoughts, the first with insight and the latter lacking
insight. In line with this concept, the category of “obses-
sions without insight” was integrated into the fourth edition
of the Diagnostic and Statistical Manual (DSM IV). OCD-
patients without insight might therefore represent a subgroup
with genetic, phenotypic and therapeutic vicinity to the
schizophrenia-like spectrum (Tumkaya et al., 2009; Catapano
et al., 2010).
Approaching the co-occurrence from the schizophrenia spec-
trum, a so-called “schizo-obsessive” subtype of psychosis has
been proposed, based on cross-sectional evaluations (Poyurovsky,
2013). This subtype has been suggested to comprise OCS in
addition to positive, negative and cognitive schizophrenia symp-
toms (Poyurovsky et al., 2012). Similar concepts have been
proposed by Hwang et al. (2000), Bottas et al. (2005), and
Reznik et al. (2001, 2005). Attempts to validate the “schizo-
obsessive” subtype on a neurobiological level have been incon-
sistent. Some studies proposed specific neurological features
(Sevincok et al., 2006; Poyurovsky et al., 2007b), cognitive deficits
(Lysaker et al., 2002, 2009) and even structural abnormalities
(Gross-Isseroff et al., 2003).
The mentioned high prevalence rates of OCS in the ARMS,
led to the perception that specific OCS could be a part of
the basic symptom cluster in the early course of schizophrenia
(Sullwold and Huber, 1986; Ebel et al., 1989).
The summarized pathogenic concepts mirror the high degree
of heterogeneity within the comorbid sample. They are currently
discussed and the number of publications on this topic nearly
doubles every year.
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Table 1 | Identification of obsessive-compulsive symptoms in schizophrenia.
Insight-criterion Patients suffering from OCD typically fulfill three symptom characteristics: they attribute the obsessions, impulsive
symptoms and compulsions to their own thinking, declare with insight their unreasonableness and show some
degree of resistance against them. In particular the first two properties allow a differentiation from hallucinations
and delusions. Ruminations or stereotypic ego-dystonic cognitions with direct relation to the contents to psychotic
thinking should not be diagnosed as obsessions.
OCS not solely related to the
psychotic content
Cleaning or checking behavior should be diagnosed as compulsions only if it is accompanied by typical obsessions
and not, if the patient currently suffers from delusions of contamination, intoxication or infection.
Re-evaluation of OCS after
remission of psychotic symptoms
If first manifestation of OCS occurs simultaneously with the first psychotic exacerbation, the final decision on a
valid comorbid condition should be postponed until the remission of psychotic symptoms.
Differentiation from catatonic
symptoms
Repetitive behavior or stereotypic actions should carefully be discriminated from catatonic symptoms most
importantly in patients with so-called “manieristic catatonia.”
Obsessions presented as
pseudohallucinations
A subgroups of OCS patients, who experience their obsessions as extremely aversive and burdening may try to
distance themselves by using expressions such as “voices” or “foreign thought content”, but in most cases these
phenomena can be characterized as pseudohallucinations.
SGA-induced OCS Patients without a previous history of OCS might develop these phenomena during antipsychotic treatment. This
constellation hints toward the unfavorable effect of second-onset OCS induced by SGAs.
Clinical aspects that have to be considered when differentiating between psychotic symptoms (delusions, hallucinations) and OCS.
UNDERLYING NEUROBIOLOGICAL MECHANISMS AND
ENVIRONMENTAL FACTORS
Neurobiology
While the described explanatory concepts mainly follow a clin-
ical or psychopathological rationale, several investigations tried
to improve the pathogenic understanding from a neurobiological
perspective. So far, most emphasis has been given to a mul-
timodal neurocognitive characterization. Preliminary investiga-
tions of neurological soft signs (Sevincok et al., 2006; Poyurovsky
et al., 2007b) and neuroimaging techniques (Gross-Isseroff et al.,
2003) need replication.
For primary OCD recent reviews of published literature
reported specific cognitive deficits especially in the areas of cog-
nitive shifting abilities, inhibitory control and the application of
effective planning strategies (Kuelz et al., 2004). Based on these
findings, the question arose whether OCS in schizophrenia might
also be linked to additional cognitive impairment in these OCD-
related domains (Lysaker andWhitney, 2009). Subsequently, sev-
eral authors tried to differentiate schizophrenia samples with vs.
without comorbid OCS on the basis of their neuropsychological
performance. Findings have been contradicting. Whereas some
investigations did not find any significant differences (Hermesh
et al., 2003; Whitney et al., 2004; Öngür and Goff, 2005; Tumkaya
et al., 2009; Tiryaki and Ozkorumak, 2010; Achim et al., 2011;
Meijer et al., 2013), others even suggested that OCS may be asso-
ciated with better cognitive abilities (Lee et al., 2009; Borkowska
et al., 2013), especially in the prodromal states of schizophrenia
(Van Dael et al., 2011; Fontenelle et al., 2012; Hur et al., 2012;
Zink et al., under review). Most results, however, showed more
pronounced deficits in the described domains of executive func-
tioning (Hwang et al., 2000; Lysaker et al., 2002, 2009), cognitive
flexibility (Kumbhani et al., 2010; Patel et al., 2010), and also
delayed visual memory (Berman et al., 1998; Schirmbeck et al.,
2011).
In a recent longitudinal assessment, Lysaker et al. prospec-
tively analyzed executive functioning and reported that deficits
were linked to greater concurrent and prospective self-report
of OCS among schizophrenia patients (Lysaker et al., 2009). A
comprehensive prospective investigation by Schirmbeck et al.
explicitly included OCD-related cognitive domains in their anal-
ysis (Kuelz et al., 2004; Rajender et al., 2011). Over a period of 12
months schizophrenia patients with comorbid OCS showed sig-
nificant pronounced deficits with increasing effect sizes regarding
cognitive flexibility, visuo-spatial perception, and visual mem-
ory. Performance in these domains correlated with OCS severity
(Schirmbeck et al., 2012b).
Based on these findings and with respect to possible causal
pathways, it has been proposed that pronounced cognitive deficits
reflect an underlying neurobiological risk factor for schizophrenia
patients to develop OCS and mirror at least partially overlap-
ping neurobiological mechanisms with OCD. In order to further
substantiate this hypothesis neurobiological links that explain the
pronounced deficits in the comorbid sample should be iden-
tified. Therefore, research should focus on candidate regions,
which have been described in primary OCD, such as increased
activation-levels in the orbitofrontal cortex (Whiteside et al.,
2004; Friedlander and Desrocher, 2006)using fMRI approaches.
Regarding neurotransmission, current pathogenic theories of
OCD assume a central serotonergic dysfunction in a network
comprising cortical, striatal and thalamic centers (Pogarell et al.,
2003). Corresponding evidence is provided by the therapeu-
tic effects of selective serotonin reuptake inhibitors (SSRIs) and
cognitive behavioral therapy (CBT) in OCD (Linden, 2006;
Saxena et al., 2009). In addition, neuroimaging studies with
structural and functional methods confirmed alterations in the
suggested network (Friedlander and Desrocher, 2006; Menzies
et al., 2008; Kwon et al., 2009a). Based on these findings it has
been assumed that the strong serotonergic antagonism of CLZ
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(Coward, 1992; Meltzer and Huang, 2008; Meltzer, 2012) and
OLZ (Duggan et al., 2000) constitute a pathogenic mechanism in
the development of second-onset OCS in schizophrenia (for more
detail see section Epidemiological evidence and Pharmacological
evidence). However, apart from serotonergic dysfunctions, alter-
ations in dopaminergic activity (Van der Wee et al., 2004) and in
glutamatergic neurotransmission, have also been related to OCD:
Support for the involvement of glutamate in the development of
OCD comes from animal models (Joel, 2006; Albelda et al., 2010;
Yang and Lu, 2011), human MR spectroscopy (Whiteside et al.,
2006; Starck et al., 2008), treatment approaches addressing the
glutamatergic system (Coric et al., 2005; Poyurovsky et al., 2005,
2010; Lafleur et al., 2006; Pittenger et al., 2006) and the following
results from genetic investigations.
Genetic disposition
Previous family and twin studies suggest a strong heritability
of OCD (Nicolini et al., 2009; Pauls, 2010). In contrast, results
from genetic association studies with a primary focus on candi-
date genes of serotonergic and dopaminergic neurotransmission
were rather ambiguous. So far, only one linkage finding has con-
sistently been replicated, which refers to single nucleotide poly-
morphisms (SNP) in the gene SLC1A1 (solute carrier family) on
chromosome 9p24, encoding the neuronal glutamate transporter
EAAC1 (excitatory amino acid carrier 1) (Veenstra-VanderWeele
et al., 2001; Arnold et al., 2006; Dickel et al., 2006; Stewart et al.,
2007; Shugart et al., 2009; Wendland et al., 2009).
Possible neurogenetic disposition to develop OCS during the
course of psychotic illness has just recently become a focus of
interest. Research within this field is still scarce and needs further
exploration. Progress has been achieved within a specific sub-
group, suggesting a genetic disposition to develop OCS during
SGA treatment (see section Genetic disposition).
Environmental factors
As briefly mentioned above, the majority of comorbid patients
reports large fluctuation of OCS severity as either remitting,
de novo development or intermittent OCS. However, the effect
of environmental factors on onset or symptom severity as well
as on interactions with other psychopathological processes has
scarcely been investigated. Thus, the small number of longitu-
dinal studies leaves important aspects unresolved. These include
the following questions: (1) Do dynamic OCS and psychotic
symptoms follow a parallel course? (2) Does a causal interac-
tion of symptom variability exist? (3) Does experienced stress,
life-events or antipsychotic medication influence the severity and
course of OCS? Detailed follow-up analyses of the potential influ-
ence of environmental factors are therefore needed. Patients,
who recently reported changes in their OCS should be investi-
gated by means of an ‘Experience Sampling Method’ (ESM). This
approach captures the reactivity to environmental factors and
the course of symptoms in detail on a day to day basis, in real
life situations, which allows to resolve symptom interactions and
contextual triggers of variability. Results could provide the basis
for individualized interventions, including adjusted modules of
cognitive behavioral therapy (CBT).
Inconsistent results regarding associated neurobiological
and environmental factors are most probably a consequence
of the reported heterogeneity within the comorbid sample.
Furthermore, methodological concerns such as the restriction to
mainly cross-sectional evaluations and a lack of power due to
small sample sizes add to inconclusive findings.
Thus, progress in pathogenic understanding seems most
likely if future research focuses on the detailed characteriza-
tion of homogeneous subsamples. One recent very promising
approach has been achieved within the subgroup of patients
who develop secondary OCS during SGA treatment. The fol-
lowing section summarizes evidence supporting the hypothe-
sis of SGA-induced OCS and introduces possible genetic risk
factors.
OCS INDUCED BY SECOND-GENERATION ANTIPSYCHOTICS
The subgroup of patients who report first onset or aggravation of
OCS after psychotic manifestation and treatment initiation with
SGAs has been brieflymentioned above. The simple assessment of
the order of three important events (first psychotic manifestation,
start of antipsychotic treatment and subsequent onset of OCS)
helps to define this subgroup (Lykouras et al., 2003; Schirmbeck
and Zink, 2012; Schirmbeck et al., 2013). The observation that
schizophrenia patients develop OCS after psychotic manifesta-
tion and treatment initiation is mainly linked to SGAs and has
rarely been reported under first generation antipsychotics. Several
authors related this observation to the fact that SGAs carry the
important pharmacodynamic feature of balanced antidopamin-
ergic and antiserotonergic properties, which markedly exceed
the low affinity of first generation antipsychotics to serotonergic
receptors (Meltzer, 1995; Meltzer et al., 2003). In addition, differ-
ential effects on GABAergic and glutamatergic neurotransmission
have to be considered (Lopez-Gil et al., 2010).
The hypothesis of SGA-inducedOCS as a side-effect (Lykouras
et al., 2003; Kwon et al., 2009b) first arose after the pioneer
observations of Baker et al. (1992) and de Haan et al. (1999).
Since then several studies show a clear association and possi-
ble causal interaction between SGA-treatment, most importantly
CLZ (Schirmbeck and Zink, 2012), and the de novo occurrence of
OCS (de Haan et al., 2004; Reznik et al., 2004; Kwon et al., 2009b;
Schirmbeck et al., 2011).
Without a doubt, CLZ must be considered an indispensable
part of the antipsychotic armament (Joober and Boksa, 2010;
Kang and Simpson, 2010; Kane, 2011; Meltzer, 2012), especially
in cases with otherwise treatment resistant psychoses (Kane et al.,
1988). Several investigations (Asenjo Lobos et al., 2010) includ-
ing the CATIE-study (McEvoy et al., 2006) have demonstrated
its superior antipsychotic efficacy (Gupta and Daniel, 1995; Still
et al., 1996; Kelly et al., 2003). Therefore, CLZ is considered the
antipsychotic of first choice in treatment resistant schizophrenia.
In addition, the substance demonstrates important anti-suicidal
effects resulting in lowmortality rates of CLZ-treated schizophre-
nia patients (Tiihonen et al., 2009). However, within a variety
of other important side effects (Asenjo Lobos et al., 2010), the
de novo occurrence or exacerbation of OCS under antipsychotic
treatment has most often been observed with CLZ (Lykouras
et al., 2003; Reznik et al., 2004; Schirmbeck and Zink, 2012).
Due to a lack of controlled clinical trials, proposed causal inter-
relations cannot be confirmed, according to the general criteria
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suggested by Bradford Hill (2011). Nevertheless, several epi-
demiological (Epidemiological evidence) and pharmacological
(Pharmacological evidence) arguments support this assumption
(for summary see Table 2).
EPIDEMIOLOGICAL EVIDENCE
Increase of OCS prevalence after market approval of SGAs
Only few investigations reported comorbidity rates in sam-
ples treated with first generation antipsychotics (Fenton and
McGlashan, 1986; Berman et al., 1995a,b; Nolfe et al., 2010). After
market approval of SGAs, most importantly CLZ, in the 1970s in
Europe and the late 1980s in the USA (Hippius, 1989; Kang and
Simpson, 2010), prevalence estimations markedly rose. Although
a potential publication bias and increased general awareness of
this topic needs to be considered, these data provide a first indirect
hint toward a possible interrelation.
Higher OCS prevalence during the chronic course of schizophrenia
As mentioned, prevalence estimations on OCS and OCD in
ARMS and first episode samples clearly vary (see Figure 1 and
section Onset of OCS). However, when compared to established
rates of 12% (OCD) and 25% (OCS) in chronic schizophrenia,
they appear to be significantly smaller. The higher rates in the later
stages of the disease might partly be attributed to antipsychotic
treatment.
Onset of de novo OCS during antipsychotic treatment or marked
aggravation
Several case reports and cases series, as well as systematic evalua-
tions describe the de novo emergence of OCS during the treatment
with atypical antipsychotics, most importantly CLZ (Schirmbeck
and Zink, 2012). Poyurovski et al. estimated that up to 70%
of schizophrenia patients treated with mainly antiserotonergic
SGAs such as CLZ, OLZ or risperidone develop secondary OCS
(Poyurovsky et al., 2004), while Lykouras et al. reviewed pub-
lished data and even reported de novo OCS in 77% of CLZ
treated patients (Lykouras et al., 2003). Independent studies
reported high proportions of SGA-induced OCS within samples
of comorbid patients: 25 of 28 (89%) (Schirmbeck et al., 2011),
29 of 39 (74%) (Lin et al., 2006) and 23 of 26 (88%) (Lim et al.,
2007). Furthermore, retrospective assessments of the individual
disease histories show that most patients experience the onset
of OCS after first manifestation of psychosis and the start with
SGA-treatment (Schirmbeck et al., 2012a) (Figure 3).
PHARMACOLOGICAL EVIDENCE
A variety of studies contribute to the assumption that antisero-
tonergic SGAs have pro-obsessive effects.
Higher prevalence of OCS in samples treated with CLZ
The risk for comorbid OCS markedly differs if patients are strat-
ified according to their mode of antipsychotic treatment. As
FIGURE 3 | In this sample of 44 comorbid patients the survival-curve
shows the events “start of SGA treatment” and “first onset of OCS”
on an individual basis related to the first manifestation of psychosis.
The longitudinal course of OCS shows a high degree of variability and is not
depicted here. The graphs shows that in all but 7 cases OCS developed
subsequently to psychosis and the vast majority of patients reported OCS
onset after treatment-start with SGAs (Schirmbeck et al., 2012a).
Table 2 | Arguments supporting SGA-induction of OCS.
Epidemiology The prevalence rates of OCS in schizophrenia increased after market approval of clozapine (Schirmbeck and Zink, 2012).
The comorbidity rates in later disease stages are higher than at first manifestation of schizophrenia (see Figure 1).
Schizophrenia patients with comorbid OCS are most frequently found to be treated with clozapine. Vice versa high OCS prevalence
in patients treated with clozapine (Poyurovsky et al., 2004; Lim et al., 2007; Poyurovsky et al., 2007a; Schirmbeck et al., 2011).
Pharmacology The type of antipsychotic treatment is associated with the risk for OCS: Marked difference between samples treated with first
generation antipsychotics or mainly dopaminergic SGAs (such as aripiprazole or amisulpride) compared to clozapine (Ertugrul et al.,
2005; Sa et al., 2009; Schirmbeck et al., 2011).
OCS manifest as a unfavorable drug effect de novo during treatment with potent antiserotonergic SGAs such as clozapine (see
Figure 3) (Schirmbeck and Zink, 2012).
The severity of OCS is positively correlated with duration, dosage and serum levels of clozapine treatment (Lin et al., 2006;
Schirmbeck et al., 2011).
The OCS severity is found stable over time in patients under stable clozapine treatment (Schirmbeck et al., 2013).
The severity of OCS improves after reduction of clozapine dosage to minimally sufficient levels (due to augmentation or
combination) (Rocha and Hara, 2006; Zink et al., 2006; Englisch et al., 2009).
Summary of epidemiological and pharmacological arguments supporting the assumption that OCS can be induced or at least markedly aggravated by SGA-treatment
as an unfavorable side effect (Schirmbeck et al., 2012b).
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reported, high prevalence rates in CLZ-treated patients (Ertugrul
et al., 2005), contrast with low rates during treatment with first
generation antipsychotics, for instance, haloperidol (Sa et al.,
2009) or other SGAs. Differences in pharmacodynamic prop-
erties, in particular regarding inherent serotonergic blockade,
monoaminergic reuptake inhibition or even partial serotoner-
gic agonism might explain these diverging findings (Shapiro
et al., 2003; Meltzer and Huang, 2008; Meltzer and Sumiyoshi,
2008; Remington, 2008; Lopez-Gil et al., 2010). Interestingly,
Aripiprazole (APZ), a partial dopaminergic and serotonergic ago-
nist, was associated with an inherent anti-obsessive effect in
schizophrenia patients with OCS (Connor et al., 2005; Zink et al.,
2006; Chang et al., 2008; Englisch and Zink, 2008; Englisch et al.,
2009), quite similar to amisulpride (AMS), a dopamine D3/D2
receptor antagonist (Kim et al., 2008; Pani et al., 2008). A compar-
ison of schizophrenia patients under antipsychotic monotherapy
with either mainly antiserotonergic SGAs (CLZ or OLZ; group I)
or mainly dopaminergic SGAs (AMS or APZ; group II) revealed
that more than 70% of group-I-patients suffered from OCS while
less than 10% of patients in group-II reported OCS (Schirmbeck
et al., 2011). Vice versa, a stratification of schizophrenia patients
according to presence or absence of comorbid OCS revealed that
77% of comorbid patients were treated with clozapine while
only 36% of schizophrenia patients without OCS received this
substance (Lim et al., 2007). These results clearly suggest an asso-
ciation between CLZ treatment and comorbid OCS. However, a
possible confounding effect due to the selection of specific SGAs
for specific subgroups of patients has to be considered.
Noteworthy, in some cases an alleviation of OCS severity
after the addition of CLZ (Peters and de, 2009), an increase
in CLZ dosage (Lykouras et al., 2003) or start with OLZ treat-
ment (van Nimwegen et al., 2008; Poyurovsky, 2013) has been
observed. Regarding these contradicting findings, some impor-
tant aspects should be discussed. One explanation relates to the
abovementioned diagnostic difficulties to differentiation between
OCS and delusional or catatonic symptoms (Table 1). Patients
with schizophrenia, who show obsessive ruminations or stereo-
typic thoughts during acute psychosis or repetitive ritualized
behavior clearly related to the patient’s primary psychotic con-
dition might indeed benefit from treatment with CLZ. Thus,
careful diagnostic evaluations are necessary. Furthermore, anti-
obsessive effects of antipsychotics have also been reported in
primary OCD, including OLZ, especially in cases with treatment-
resistance to serotonergic antidepressants (Bloch et al., 2006;
Bandelow et al., 2008; Dold et al., 2011; Muscatello et al., 2011).
Nevertheless, even in treatment-resistant OCD current treat-
ment guidelines do not recommend CLZ as an augmentation
strategy.
Associations between the duration of treatment and OCS severity
Correlations between pharmacological variables and OCS pro-
vide further support for proposed causal interactions. Lin et al.
(2006) compared CLZ-treated patients with and without comor-
bid OCS and found significantly longer CLZ treatment periods
for the comorbid group, but no difference in duration of illness.
Schirmbeck et al. reported a positive correlation between OCS
severity and duration of CLZ-treatment (Schirmbeck et al., 2011).
Accordingly, de Haan et al. reported this association for OLZ (de
Haan et al., 2002).
ASSOCIATION BETWEEN DOSAGE AND BLOOD SERUM LEVELS AND
OCS SEVERITY
Several authors demonstrated positive correlations between dose
or serum levels of CLZ and severity of OCS (Lin et al., 2006;
Reznik et al., 2004; Mukhopadhaya et al., 2009; Schirmbeck
et al., 2011). Similarly, a reduction of daily CLZ-dosage, for
instance through the combinations with another SGA, such as
APZ, resulted in an alleviation of OCS severity (Rocha and Hara,
2006; Zink et al., 2006; Englisch et al., 2009). This observed effect
might represent both a reduction of the suggested dose-related
side effect of CLZ and/or a consequence of inherent anti-obsessive
effects of APZ due to its partial dopaminergic and serotoner-
gic agonism. The latter assumption was supported by a placebo
controlled randomized trial, which showed reduced OCS severity
after combination with APZ, but unchanged CLZ dose during the
course of the study (Chang et al., 2008).
Differential effects of SGAs on the course of OCS
A recent longitudinal study revealed differential effects of antipsy-
chotic agents on comorbid OCS. Within a 12 months obser-
vational period, changes in YBOCS scores significantly differed
between two pharmacologically diverse groups (completer anal-
ysis: p = 0.006; full sample analysis: p = 0.007). Whereas the
CLZ/OLZ group showed persistently high OCS severity over time,
the AMS/APZ group reported further decrease of the initially low
YBOCS-scores (Schirmbeck et al., 2013).
In conclusion, reported data show strong associations between
comorbid OCS in schizophrenia and mainly antiserotonergic
SGAs, most importantly CLZ. The published epidemiologi-
cal and pharmacological evidence hint toward causal interac-
tions, suggesting CLZ’s strong inherent antiserotonergic proper-
ties (Steingard et al., 1993; Joober and Boksa, 2010; Kang and
Simpson, 2010), most importantly the antagonism at 5-HT1C,
5-HT2A and 5HT2C receptors (Coward, 1992; Meltzer, 1994;
Meltzer and Huang, 2008) as an relevant underlying mechanism.
Low affinities to dopamine receptors result in a very small ratio of
dopaminergic/serotonergic receptor blockade, which largely dif-
fers from SGAs such as AMS or APZ (Scatton et al., 1997; Shapiro
et al., 2003; Correll, 2008). In addition, reciprocal interactions
of dopaminergic and serotonergic neurotransmission with glu-
tamatergic and GABAergic functions might play an important
role (Lopez-Gil et al., 2010). Thus, pharmacotherapy constitutes
a relevant environmental factor, which might exert pro-obsessive
effects in schizophrenia patients. Within a broader perspective,
additional questions arise concerning predisposing factors. These
might comprise patient-inherent characteristics (neurocognitive
profile, the subtype of psychosis, the stage of the illness, any kind
of affective comorbidity or a family history for anxiety disorders)
and the individual genetic disposition.
GENETIC DISPOSITION
Associations with the gene SLC1A1 have consistently been repli-
cated in primary OCD patients. Based on these findings a
South Korean research group investigated the genetic risk to
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develop second-onset OCS during treatment with SGAs (Kwon
et al., 2009b). Kwon et al evaluated associations between spe-
cific SNPs of the candidate gene SLC1A1 and SGA-induced OCS
and showed strong associations with the A/C/G dominant haplo-
type rs2228622 / rs3780413 / rs37801412. The odds ratio of 3.96
indicated an almost 4 times higher likelihood for patients, who
carried this A/C/G haplotype to suffer from SGA-induced OCS.
Neither the gene SLC1A1 nor its chromosomal region has been
associated with vulnerability to schizophrenia spectrum disorders
(Deng et al., 2007). The same group further described a genetic
interaction of the SLC1A1 polymorphism with variants in the
geneDLGAP3 (disks large associated protein 3) and a link to SGA-
induced OCS (Ryu et al., 2011). In addition, Cai et al reported
on an interaction of SNPs in SLC1A1 and the type 2B subunit
of the N-methyl-D-aspartate receptor gene (GRIN2B), as well as
interactions with the YBOCS score in Chinese patients (Cai et al.,
2013).
A replication approach of the results obtained by Kwon et al.
(2009b) was conducted in 103 schizophrenia patients of European
descent treated with SGAs. However, the described finding could
not be reproduced, neither in single marker, nor in haplotype
analyses. Because no genetic associations between SLC1A1 poly-
morphisms and OCS were found within the power limits of
this study, much larger samples seem necessary to untangle the
interplay of pharmacological and genetic risk factors for OCS
in schizophrenia (Schirmbeck et al., 2012a). The brain derived
neurotrophic factor (BDNF) was recently proposed as a third can-
didate gene, because the Val66Met polymorphism was found to
be associated with OCS in schizophrenia (Hashim et al., 2012).
So far, independent replication approaches regarding BDNF,
DLGAP3 and GRIN2B have not been conducted.
RESEARCH PERSPECTIVES
GxEI ON A SECOND LEVEL OF COMPLEXITY
GxEIs are core elements within current theories of schizophrenia
(van Os and Kapur, 2009; van Os et al., 2008, 2010), depres-
sion (Keers and Uher, 2012), anxiety disorders (Gregory et al.,
2008; Nugent et al., 2011) and OCD (Nicolini et al., 2009; Pauls,
2010). High rates of bi-directional comorbidities lead to the obvi-
ous question, if these co-occurrences could also be explained by
common GxEIs. One example of this experimental psychopathol-
ogy has been illustrated by the described investigation of the risk
to develop secondary OCS during treatment with SGAs. Here,
the environmental factor is represented in the pharmacological
treatment of schizophrenia with pro-obsessive SGAs.
As stated in chapter 4, SGAs increase the risk for secondary
OCS via a pharmacodynamic mechanism. Independently, a set
of SNPs within the gene SLC1A1 seem to predispose to OCD.
However, the initially reported high odds ratio by Kwon et al.
(2009b) could not be replicated in a similar study performed with
European patients (Schirmbeck et al., 2012a). Thus, the general
genetic background of a patient (Asian or European) might be of
importance when a specific SGA (balance between dopaminer-
gic and serotonerigic blockade) is introduced as the treatment of
choice. Furthermore, gene-x-gene interactions (SNPs in SLC1A1,
BDNF, DLGAP3, and GRIN2B) have been suggested as further
influencing factors (Ryu et al., 2011; Hashim et al., 2012) and
should be considered in forthcoming studies. It is an important
progress in recent neurobiological research to investigate how
the interaction of these factors might influence the propensity of
schizophrenia patients to suffer from comorbid OCS when being
treated with SGAs.
Future progress might depend on two aspects: First, well
defined homogeneous clinical cohorts should be defined to
reduce the number of possible confounding causal factors to a
minimum. Considering the order of symptom onset, the clin-
ical course and the applied treatment for sample characteriza-
tion might be helpful. Second, much larger cohorts have to be
recruited in multicenter studies to investigate possible genetic
risk constellations. If power analyses would be based on the
much smaller genetic-risk estimations for the gene SLC1A1 in the
European sample (Schirmbeck et al., 2012a), group size calcula-
tions result in about five thousand participants, which would be
necessary for replication.
Besides pharmacological treatment as a relevant factor, fur-
ther non-pharmacological environmental factors could play an
important role in the development of OCS in schizophrenia.
Such factors might include, psychosocial stress induced by critical
life events, interpersonal factors, changes of the vocational situ-
ation or the present state of general physical health. In addition,
the reciprocal interaction and possible causal directions between
OCS and psychotic positive, negative and cognitive symptoms
of schizophrenia must be unraveled and considered. One impor-
tant tool to unravel the interdependence of these variables are the
above described experience sampling approaches. These allow to
investigate the individual symptom variability in real life situa-
tions on a day to day basis.
Collected data will help to identify the time course of
symptom-changes and its relation to important environmental
factors. These studies are currently planned and will hopefully
result in an improved understanding of etiological factors influ-
encing the course of OCS in schizophrenia. Within this context it
will also be desirable to collect DNA samples in order to analyse
possible predisposing effects of the above mentioned polymor-
phisms to experience the development or aggravation of OCS
after being exposed to stressful life events. Thus, combining expe-
rience sampling and genetic characterizations might markedly
improve our insight into GxEI.
THERAPY
At present, pharmacological treatment interventions, most
importantly combination as well as augmentation strategies, have
been suggested to improve OCS in the highly impaired comorbid
group (Schirmbeck et al., 2013). To address possible pro-obsessive
effects of predominantly anti-serotonergic SGAs, the add-on of
mainly dopaminergic SGAs such as AMS and APZ has been pro-
posed (Connor et al., 2005; Zink et al., 2006; Englisch and Zink,
2008; Kim et al., 2008; Yang et al., 2008; Englisch et al., 2009;
Muscatello et al., 2011). In addition, the augmentation with sero-
tonergic antidepressants has been evaluated, for example with the
tricyclic antidepressant clomipramine (Berman et al., 1995b) or
with SSRIs, most often fluvoxamine (Poyurovsky et al., 1999b;
Reznik and Sirota, 2000; Hwang et al., 2009). Results of these trials
have been inconsistent with some studies failing to observe the
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Monitoring of subclinical levels of OCS or beginning cognitive impairment using sensitive sets of neurocognitive tests
(Schirmbeck et al., 2011, 2012b).
Polypharmacy Augmentation with antidepressants: Clomipramine, fluvoxamine and other SSRIs. [Level of evidence: RCTs, CS, CR] (Berman
et al., 1995b; Poyurovsky et al., 1999b; Reznik and Sirota, 2000).
Caveat: Additive (anticholinergic) side effects and pharmacokinetic interactions
Augmentation with mood stabilizers (lamotrigine, valproic acid) aiming at a reduction of SGA-dosage to minimally sufficient levels
[Level of evidence: CS, CR] (Zink et al., 2007; Poyurovsky et al., 2010; Rodriguez et al., 2010; Canas et al., 2012).
Combination of pro-obsessive SGAs with neutral or anti-obsessive SGAs (amisulpride, aripiprazole) in order to reduce the
clozapine-dosage to minimally sufficient levels [Level of evidence: RCT, CS, CR].
(Connor et al., 2005; Zink et al., 2006; Englisch and Zink, 2008; Kim et al., 2008; Yang et al., 2008; Englisch et al., 2009;
Muscatello et al., 2011)
Psychotherapy Cognitive behavioral therapy involving exposure and response prevention [Level of evidence: CS, CR] (Schirmbeck and Zink, 2012;
Tundo et al., 2012).
Summary of therapeutic approaches for schizophrenia patients with comorbid OCS or OCD. The current level of empirical evidence is indicated in square brackets.
Abbreviations: CR, case report; CS, case series; RCT, randomized controlled trial.
intended effects of OCS reduction. Furthermore, additive anti-
cholinergic side effects and pharmacokinetic interactions have
to be considered. Finally, first promising results were published
reporting on the augmentation with mood stabilizers such as val-
proic acid (Zink et al., 2007; Canas et al., 2012) or lamotrigine
(Poyurovsky et al., 2010; Rodriguez et al., 2010).
So far, very limited data exists on the efficacy and safety of cog-
nitive behavioral therapy (CBT) for this group of patients. The
small number of case reports and case series can hardly be rec-
onciled with the fact, that CBT including exposure and response
prevention is considered treatment of first choice for primary
OCD with remarkably high effect sizes (Gava et al., 2007; Koran
et al., 2007; Rosa-Alcazar et al., 2008; Kuelz and Voderholzer,
2011). With one exception, currently available CBT manuals for
OCD do not provide guidelines for the treatment of OCS in
schizophrenia (Emmelkamp and van Oppen, 2000; Lakatos and
Reinecker, 2007; Oelkers et al., 2007; Foerstner et al., 2011).
However, a summary of the published reports on 30 comor-
bid patients (Schirmbeck et al., 2013), who were treated with
CBT including exposure elements or just exposure and response
prevention alone showed favorable outcome measures with sig-
nificant reduction of OCD severity in 24 patients. In the included
case series by Tundo et al. (2012) 52% of investigated individuals
were classified as “much or very much” improved, 33% as respon-
ders and 19% as remitters. The available evidence of CBT for OCS
in schizophrenia is certainly limited by the small case numbers
and further controlled clinical trials are needed. However, despite
adverse clinical outcomes in 10%, and a total dropout rate of
20%, preliminary results suggest meaningful and marked reduc-
tion of OCS severity in 80% of participants (Schirmbeck et al.,
2013). Table 3 summarizes possible pharmacological and non-
pharmacological approaches and current evidence of empirical
support.
CONCLUSIONS
The summarized data substantiate the conclusions that OCS is
a very frequent and relevant comorbid burden in schizophre-
nia. The clinical presentation of the co-occurrence is very diverse,
suggesting different subgroups with heterogeneous pathogenic
mechanisms. First insight into GxEI has been achieved for the
subgroup of patients who experienced second-onset OCS during
treatment with SGAs. In the future, a broader set of environ-
mental variables, including non-pharmacological factors, and
further genetic risk-constellations should be analysed, starting
in the ARMS. In perspective, this will not only improve the
risk prediction regarding comorbid OCS, but also early recog-
nition and monitoring of emerging symptoms. Research within
this field will further provide the individual framework of predis-
posing and disease-provoking factors with immediate impact for
pharmacological and CBT approaches.
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